FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Previous Screen

Irinotecan Hydrochloride Injection
Status: Discontinuation
»Therapeutic Categories: Oncology

Expand all

Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) (New 09/26/2025)

Company Contact Information:
Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)

Presentation	Posting Date	Related Information
Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02)	09/26/2025	Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals
Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 25021-230-05)	09/26/2025	Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals

Teva Pharmaceuticals USA, Inc. (New 08/04/2025)

Company Contact Information:
800-545-8800

Presentation	Posting Date	Related Information
Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-51)	08/04/2025	Product not anticipated to be available beyond mid-late October 2025
Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-55)	08/04/2025	Product not anticipated to be available beyond mid-late September 2025